Format

Send to

Choose Destination
Acta Ophthalmol. 2016 Dec;94(8):e744-e752. doi: 10.1111/aos.13069. Epub 2016 May 20.

The German ROP Registry: data from 90 infants treated for retinopathy of prematurity.

Author information

1
Eye Center, University of Freiburg, Freiburg, Germany.
2
Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany.
3
Department of Ophthalmology, University Medical Center Göttingen, Göttingen, Germany.
4
University Eye Hospital, Hannover Medical School, Hannover, Germany.
5
University Eye Hospital, Eberhard-Karl University Tübingen, Tübingen, Germany.
6
University Eye Hospital, University of Oldenburg, Oldenburg, Germany.
7
Department of Ophthalmology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
8
Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany.
9
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
10
Department of Ophthalmology, Vivantes Klinikum Neukölln, Berlin, Germany.
11
Department of Ophthalmology, University of Bonn, Bonn, Germany.

Abstract

PURPOSE:

The German retinopathy of prematurity (ROP) Registry collects data on treated ROP in a multicentre approach to analyse epidemiology and treatment patterns of severe ROP.

METHODS:

Nine centres entered data from 90 treated ROP infants (born between January 2011 and December 2013) into a central database. Analysis included incidence rate of severe ROP, demographic data, stage of ROP, treatment patterns, recurrence rates, relevant comorbidities and ophthalmological or systemic complications associated with treatment.

RESULTS:

Treatment rate for ROP was 3.2% of the screened population. The most frequent ROP stage at time of treatment was zone II, stage 3 +  (137 eyes). Treatment was bilateral in 97% of infants. Treatment patterns changed over time from 7% anti-vascular endothelial growth factor (VEGF) monotherapy in 2011 to 32% in 2014. Overall, laser treatment was the predominant treatment. However, all infants with zone I disease received anti-VEGF treatment. About 19% of infants required retreatment (16% of laser-treated and 21% of anti-VEGF treated infants). Mean time between first and second treatment was 3.8 weeks (± 11 days) for laser-treated and 10.4 weeks (± 60 days) for anti-VEGF-treated infants.

CONCLUSION:

This study is the first multicentre analysis of severe ROP in Germany. The identified treatment patterns find laser as the most prevalent form of therapy, with an increasing use of anti-VEGF therapy over recent years. Recurrence rates were relatively high overall with slightly higher recurrence rates and later recurrence times in the anti-VEGF group. Anti-VEGF was predominantly used for high-risk stages like AP-ROP and zone I disease.

KEYWORDS:

anti-VEGF; laser; retinopathy of prematurity; treatment pattern

PMID:
27197876
DOI:
10.1111/aos.13069
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center